This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (546)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Prognosis/ Outcomes  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Ioannis Iakovou, MD; Thomas Schmidt, MD; Erminio Bonizzoni, PhD; Lei Ge, MD; Giuseppe M. Sangiorgi, MD; Goran Stankovic, MD; Flavio Airoldi, MD; Alaide Chieffo, MD; Matteo Montorfano, MD; Mauro Carlino, MD; Iassen Michev, MD; Nicola Corvaja, MD; Carlo Briguori, MD; Ulrich Gerckens, MD; Eberhard Grube, MD; Antonio Colombo, MD

JAMA. 2005;293:2126-2130.

Context  Traditionally, stent thrombosis has been regarded as a complication of percutaneous coronary interventions during the first 30 postprocedural days. However, delayed endothelialization associated with the implantation of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data are limited regarding the risks and the impact of this phenomenon outside clinical trials.

Objective  To evaluate the incidence, predictors, and clinical outcome of stent thrombosis after implantation of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice.

Design, Setting, and Patients  Prospective observational cohort study conducted at 1 academic hospital and 2 community hospitals in Germany and Italy. A total of 2229 consecutive patients underwent successful implantation of sirolimus-eluting (1062 patients, 1996 lesions, 2272 stents) or paclitaxel-eluting (1167 patients, 1801 lesions, 2223 stents) stents between April 2002 and January 2004.

Interventions  Implantation of a drug-eluting stent (sirolimus or paclitaxel). All patients were pretreated with ticlopidine or clopidogrel and aspirin. Aspirin was continued indefinitely and clopidogrel or ticlopidine for at least 3 months after sirolimus-eluting and for at least 6 months after paclitaxel-eluting stent implantation.

Main Outcome Measures  Subacute thrombosis (from procedure end through 30 days), late thrombosis (>30 days), and cumulative stent thrombosis.

Results  At 9-month follow-up, 29 patients (1.3%) had stent thrombosis (9 [0.8%] with sirolimus and 20 [1.7%] with paclitaxel; P = .09). Fourteen patients had subacute thrombosis (0.6%) and 15 patients had late thrombosis (0.7%). Among these 29 patients, 13 died (case fatality rate, 45%). Independent predictors of stent thrombosis were premature antiplatelet therapy discontinuation (hazard ratio [HR],  89.78; 95% CI, 29.90-269.60; P<.001), renal failure (HR,  6.49; 95% CI, 2.60-16.15; P<.001), bifurcation lesions (HR,  6.42; 95% CI, 2.93-14.07; P<.001), diabetes (HR,  3.71; 95% CI, 1.74-7.89; P = .001), and a lower ejection fraction (HR,  1.09; 95% CI, 1.05-1.36; P<.001 for each 10% decrease).

Conclusions  The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials. Premature antiplatelet therapy discontinuation, renal failure, bifurcation lesions, diabetes, and low ejection fraction were identified as predictors of thrombotic events.

Author Affiliations: Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy (Drs Iakovou, Ge, Sangiorgi, Stankovic, Airoldi, Chieffo, Montorfano, Carlino, Michev, Corvaja, Briguori, and Colombo); Mediolanum Cardio Research, Milan, Italy (Dr Sangiorgi); Department of Cardiology, Klinikum Siegburg Rhein-Sieg GmbH, Siegburg, Germany (Drs Schmidt, Gerckens, and Grube); and Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy (Dr Bonizzoni).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Thrombosis After Implantation of Drug-Eluting Stents
, , , and
JAMA. ;295():36-36.
FULL TEXT  

Thrombosis After Implantation of Drug-Eluting Stents--Reply
and
JAMA. ;295():36-36.
FULL TEXT  

RELATED ARTICLE

Drug-Eluting Stents in Acute Myocardial Infarction: Is Science Catching Up With Practice?
and
JAMA. ;293():2154-2156.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
American College of Cardiology Foundation et al.
J Am Coll Cardiol 2009;0:j.jacc.2009.07.010v1-15023.
FULL TEXT  

Perioperative management of warfarin and antiplatelet therapy
JAFFER
Cleveland Clinic Journal of Medicine 2009;76:S37-S44.
ABSTRACT | FULL TEXT  

Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards.
Kandzari et al.
J Am Coll Cardiol 2009;54:1576-1588.
ABSTRACT | FULL TEXT  

Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
Geisler et al.
Eur Heart J 2009;0:ehp402v1-ehp402.
ABSTRACT | FULL TEXT  

Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial: Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
Kirtane et al.
J Am Coll Cardiol Intv 2009;2:967-976.
ABSTRACT | FULL TEXT  

Optimal Stent-Sizing With Intravascular Ultrasound Contributes to Complete Neointimal Coverage After Sirolimus-Eluting Stent Implantation Assessed by Angioscopy
Sera et al.
J Am Coll Cardiol Intv 2009;2:989-994.
ABSTRACT | FULL TEXT  

Optimal Stent Expansion and Complete Neointimal Coverage: Does This Association Make Sense?
Mintz and Choi
J Am Coll Cardiol Intv 2009;2:995-996.
FULL TEXT  

Stent Thrombosis in Sweden: A Report From the Swedish Coronary Angiography and Angioplasty Registry
Lagerqvist et al.
Circ Cardiovasc Interv 2009;2:401-408.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry
Harjai et al.
Heart 2009;95:1579-1586.
ABSTRACT | FULL TEXT  

Quality of care for atrial fibrillation among patients hospitalized for heart failure.
Piccini et al.
J Am Coll Cardiol 2009;54:1280-1289.
ABSTRACT | FULL TEXT  

Long-Term Outcome of Drug-Eluting Stents Compared With Bare Metal Stents in ST-Segment Elevation Myocardial Infarction: Results of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial
Di Lorenzo et al.
Circulation 2009;120:964-972.
ABSTRACT | FULL TEXT  

Long-Term Safety and Effectiveness of Unprotected Left Main Coronary Stenting With Drug-Eluting Stents Compared With Bare-Metal Stents
Kim et al.
Circulation 2009;120:400-407.
ABSTRACT | FULL TEXT  

Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis
Cook and Wenaweser
Circ Cardiovasc Interv 2009;2:273-276.
FULL TEXT  

Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel
Lokhandwala et al.
Circ Cardiovasc Interv 2009;2:348-351.
ABSTRACT | FULL TEXT  

Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries
Lasala et al.
Circ Cardiovasc Interv 2009;2:285-293.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?
Drachman
Circulation 2009;120:101-103.
FULL TEXT  

Combining Antiplatelet and Anticoagulant Therapies.
Holmes et al.
J Am Coll Cardiol 2009;54:95-109.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization: Analysis From the NCDR (National Cardiovascular Data Registry)
Frutkin et al.
J Am Coll Cardiol Intv 2009;2:614-621.
ABSTRACT | FULL TEXT  

Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents
Camici et al.
Eur Heart J 2009;0:ehp259v1-ehp259.
ABSTRACT | FULL TEXT  

Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Unverdorben et al.
Circulation 2009;119:2986-2994.
ABSTRACT | FULL TEXT  

Coronary aneurysms after drug-eluting stent implantation clinical, angiographic, and intravascular ultrasound findings.
Alfonso et al.
J Am Coll Cardiol 2009;53:2053-2060.
ABSTRACT | FULL TEXT  

Percutaneous coronary intervention versus coronary artery bypass surgery in multivessel disease: a current perspective
Soran et al.
ICVTS 2009;8:666-671.
ABSTRACT | FULL TEXT  

Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
Leon et al.
J Am Coll Cardiol Intv 2009;2:504-512.
ABSTRACT | FULL TEXT  

The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial
Di Lorenzo et al.
J Am Coll Cardiol Intv 2009;2:515-523.
ABSTRACT | FULL TEXT  

A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
Takagi et al.
J Am Coll Cardiol Intv 2009;2:524-531.
ABSTRACT | FULL TEXT  

Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use
Anwaruddin et al.
J Am Coll Cardiol Intv 2009;2:542-549.
ABSTRACT | FULL TEXT  

Impact of Intravascular Ultrasound Guidance on Long-Term Mortality in Stenting for Unprotected Left Main Coronary Artery Stenosis
Park et al.
Circ Cardiovasc Interv 2009;2:167-177.
ABSTRACT | FULL TEXT  

Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
To et al.
Circ Cardiovasc Interv 2009;2:213-221.
ABSTRACT | FULL TEXT  

Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Chevalier et al.
Circ Cardiovasc Interv 2009;2:188-195.
ABSTRACT | FULL TEXT  

Update on dual antiplatelet therapy for percutaneous coronary intervention
Prasad and Holmes
Heart 2009;95:861-865.
FULL TEXT  

Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.
Ko et al.
J Am Coll Cardiol 2009;53:1773-1782.
ABSTRACT | FULL TEXT  

Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden
James et al.
NEJM 2009;360:1933-1945.
ABSTRACT | FULL TEXT  

Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.
Brar et al.
J Am Coll Cardiol 2009;53:1677-1689.
ABSTRACT | FULL TEXT  

Unprotected Left Main Stenting in the Real World: Two-Year Outcomes of the French Left Main Taxus Registry
Vaquerizo et al.
Circulation 2009;119:2349-2356.
ABSTRACT | FULL TEXT  

Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography
Otake et al.
J Am Coll Cardiol Intv 2009;2:459-466.
ABSTRACT | FULL TEXT  

Reply
Lee et al.
J Am Coll Cardiol Intv 2009;2:474-475.
FULL TEXT  

Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
Weisz et al.
J Am Coll Cardiol 2009;53:1488-1497.
ABSTRACT | FULL TEXT  

Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry
van Werkum et al.
J Am Coll Cardiol 2009;53:1399-1409.
ABSTRACT | FULL TEXT  

Rapamycin-Eluting Stents in the Arterial Duct: Experimental Observations in the Pig Model
Lee et al.
Circulation 2009;119:2078-2085.
ABSTRACT | FULL TEXT  

Clopidogrel in acute coronary syndromes
Chua and Ignaszewski
BMJ 2009;338:b1180-b1180.
FULL TEXT  

Restenosis Revisited
Calvert and Bennett
Circ. Res. 2009;104:823-825.
FULL TEXT  

Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
Ruiz-Nodar et al.
Eur Heart J 2009;30:932-939.
ABSTRACT | FULL TEXT  

In Vivo Assessment of High-Risk Coronary Plaques at Bifurcations With Combined Intravascular Ultrasound and Optical Coherence Tomography
Gonzalo et al.
J Am Coll Cardiol Img 2009;2:473-482.
ABSTRACT | FULL TEXT  

The Excel Stent: A Good DES, But Can We Really Stop Clopidogrel After 6 Months?
Margolis
J Am Coll Cardiol Intv 2009;2:310-311.
FULL TEXT  

Symptomatic Ostial Vertebral Artery Stenosis: Treatment with Drug-eluting Stents--Clinical and Angiographic Results at 1-year Follow-up
Yu et al.
Radiology 2009;251:224-232.
ABSTRACT | FULL TEXT  

Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Eisenberg et al.
Circulation 2009;119:1634-1642.
ABSTRACT | FULL TEXT  

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing et al.
J Am Coll Cardiol 2009;53:849-856.
ABSTRACT | FULL TEXT  

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes
Budaj et al.
Eur Heart J 2009;30:655-661.
ABSTRACT | FULL TEXT  

Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions: Clinical and Angiographic Long-Term Outcome After Implantation of Drug-Eluting Stents
Galassi et al.
J Am Coll Cardiol Intv 2009;2:185-194.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention Treatment of Bifurcation Lesions--A Work in Progress: The Importance of Single-Center Studies
Kaplan
J Am Coll Cardiol Intv 2009;2:195-196.
FULL TEXT  

3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents
Applegate et al.
J Am Coll Cardiol Intv 2009;2:231-239.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
Kimura et al.
Circulation 2009;119:987-995.
ABSTRACT | FULL TEXT  

Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis: An Analysis of 431 Cases
van Werkum et al.
Circulation 2009;119:828-834.
ABSTRACT | FULL TEXT  

Early Stent Thrombosis: Past, Present, and Future
Cook and Windecker
Circulation 2009;119:657-659.
FULL TEXT  

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
Stone et al.
Circulation 2009;119:680-686.
ABSTRACT | FULL TEXT  

Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial
Aoki et al.
Circulation 2009;119:687-698.
ABSTRACT | FULL TEXT  

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Kuliczkowski et al.
Eur Heart J 2009;30:426-435.
ABSTRACT | FULL TEXT  

Drug-eluting stent thrombosis
Stahli et al.
Ther Adv Cardiovasc Dis 2009;3:45-52.
ABSTRACT  

Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events
Steg et al.
Eur Heart J 2009;30:321-329.
ABSTRACT | FULL TEXT  

Percutaneous Revascularization of Grafts Versus Native Coronary Arteries in Postcoronary Artery Bypass Graft Patients
Garcia-Tejada et al.
ANGIOLOGY 2009;60:60-66.
ABSTRACT  

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care
Cohen
Mayo Clin Proc. 2009;84:149-160.
ABSTRACT | FULL TEXT  

Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis
Hassan et al.
Eur Heart J 2009;0:ehn553v1-9.
ABSTRACT | FULL TEXT  

Are drug-eluting stents safe in the long term?
Genereux and Mehran
CMAJ 2009;180:154-155.
FULL TEXT  

Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study
Colombo et al.
Circulation 2009;119:71-78.
ABSTRACT | FULL TEXT  

Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
Authors/writing members: et al.
Eur Heart J 2009;30:152-161.
FULL TEXT  

An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events
Terpening
J Am Board Fam Med 2009;22:51-56.
ABSTRACT | FULL TEXT  

Antiplatelet Agents in the Perioperative Period
O'Riordan et al.
Arch Surg 2009;144:69-76.
ABSTRACT | FULL TEXT  

In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
Latif et al.
J Am Coll Cardiol Intv 2009;2:37-45.
ABSTRACT | FULL TEXT  

Endothelialization and late stent thrombosis in diabetics.
Kaneda
J Am Coll Cardiol 2008;52:2213-2213.
FULL TEXT  

Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia
Park and Kim
Circulation 2008;118:2730-2737.
FULL TEXT  

Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study
Burzotta et al.
Eur Heart J 2008;29:3011-3021.
ABSTRACT | FULL TEXT  

Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof?
Shemin
Circulation 2008;118:2326-2329.
FULL TEXT  

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Chhatriwalla and Bhatt
Circ Cardiovasc Interv 2008;1:217-225.
FULL TEXT  

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Colombo and Gerber
Circ Cardiovasc Interv 2008;1:226-232.
FULL TEXT  

Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes
Adriaenssens et al.
Eur Heart J 2008;29:2868-2876.
ABSTRACT | FULL TEXT  

Comparison of Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy
Lee et al.
J Am Coll Cardiol Intv 2008;1:710-715.
ABSTRACT | FULL TEXT  

Coronary stent thrombosis in the perioperative period
Cruden et al.
BMJ 2008;337:a2074-a2074.
FULL TEXT  

Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts
Mauri et al.
Circulation 2008;118:1817-1827.
ABSTRACT | FULL TEXT  

Management of Patients After Percutaneous Coronary Interventions
Shoulders-Odom
Crit Care Nurse 2008;28:26-40.
FULL TEXT  

Acute and long-term outcome of unprotected left main coronary angioplasty compared to the anticipated surgical risk
Rademacher et al.
ICVTS 2008;7:871-877.
ABSTRACT | FULL TEXT  

Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents
Park et al.
J Am Coll Cardiol Intv 2008;1:494-503.
ABSTRACT | FULL TEXT  

Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
Wenaweser et al.
J Am Coll Cardiol 2008;52:1134-1140.
ABSTRACT | FULL TEXT  

Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality
Shishehbor et al.
J Am Coll Cardiol 2008;52:1041-1048.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention for Stable Coronary Artery Disease
Katritsis and Meier
J Am Coll Cardiol 2008;52:889-893.
ABSTRACT | FULL TEXT  

Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised
Pfisterer
Circulation 2008;118:1117-1119.
FULL TEXT  

Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study
Nakazawa et al.
Circulation 2008;118:1138-1145.
ABSTRACT | FULL TEXT  

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
Angiolillo et al.
Eur Heart J 2008;29:2202-2211.
ABSTRACT | FULL TEXT  

Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures
Veitch et al.
Gut 2008;57:1322-1329.
FULL TEXT  

A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
Lee et al.
J Am Coll Cardiol 2008;52:727-733.
ABSTRACT | FULL TEXT  

Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
Gori et al.
J Am Coll Cardiol 2008;52:734-739.
ABSTRACT | FULL TEXT  

Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Mehilli et al.
Eur Heart J 2008;29:1975-1982.
ABSTRACT | FULL TEXT